Lisdexamfetamine
- Generic Name
- Lisdexamfetamine
- Brand Names
- Vyvanse
- Drug Type
- Small Molecule
- Chemical Formula
- C15H25N3O
- CAS Number
- 608137-32-2
- Unique Ingredient Identifier
- H645GUL8KJ
- Background
Lisdexamfetamine is a prodrug of dextroamphetamine, a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved by Health Canada in February 2009. Lisde...
- Indication
Lisdexamfetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients six years and older. It is also indicated to treat moderate to severe binge eating disorder (BED) in adults. It is approved for use in the US and Canada.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Moderate Binge Eating Disorder (BED), Severe Binge Eating Disorder (BED)
- Associated Therapies
- -
Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)
- First Posted Date
- 2009-04-29
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- Duke University
- Target Recruit Count
- 228
- Registration Number
- NCT00889915
- Locations
- 🇺🇸
Child and Adolescent Psychiatry Trials Network (CAPTN), Durham, North Carolina, United States
Effect of Vyvanse on Sleep in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder (ADHD)
- Conditions
- Interventions
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2008-12-11
- Lead Sponsor
- Clinical Study Centers, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT00807222
- Locations
- 🇺🇸
Clinical Study Centers, LLC, Little Rock, Arkansas, United States
Effect of Vyvanse on Driving in Young Adults With ADHD
- Conditions
- Interventions
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2014-03-10
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT00801229
- Locations
- 🇺🇸
Massachusetts General Hospital, Cambridge, Massachusetts, United States
Compare Subjective Drug Liking & Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as an Oral Solution
- Conditions
- Interventions
- First Posted Date
- 2008-10-21
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Shire
- Target Recruit Count
- 3
- Registration Number
- NCT00776555
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults
- Conditions
- Interventions
- First Posted Date
- 2008-09-16
- Last Posted Date
- 2012-09-24
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT00753012
- Locations
- 🇺🇸
Massachusetts General Hospital, Cambridge, Massachusetts, United States
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
- Conditions
- Interventions
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Shire
- Target Recruit Count
- 24
- Registration Number
- NCT00746733
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading
- First Posted Date
- 2008-08-13
- Last Posted Date
- 2018-02-14
- Lead Sponsor
- Kimberley Lakes
- Target Recruit Count
- 42
- Registration Number
- NCT00733356
- Locations
- 🇺🇸
University of California, Irvine Child Development Center, Irvine, California, United States
Pilot Study of Vyvanse™ In ADHD Adolescents at Risk for Substance Abuse
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 8
- Registration Number
- NCT00573534
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.